PURPOSE: To evaluate the potential role, safety, and efficacy of @entity1311 -eluting balloon angioplasty for treatment of recurrent carotid in-stent restenosis (ISR). METHODS: Among 856 consecutive @entity1 who underwent carotid artery stenting from May 2002 to January 2008, 41 @entity1 had a significant ISR (>80% @entity850 ). Of these, 9 @entity1 (7 @entity1 ; mean age 78.1  5.6 years) had recurrent ISR despite multiple endovascular treatments (3.4  0.9 interventions) within a short period of time (2-5 months). These @entity1 were treated with @entity661 for @entity1373 . Imaging (ultrasound or computed tomographic angiography) was performed at 1, 3, and 6 months and yearly thereafter. RESULTS: Technical success was obtained in 100% of cases, with angiographic @entity850 decreasing from 87%  4% to 6%  4% post treatment. Peak systolic velocity decreased significantly from 4.7  1.5 m/s to 0.6.  0.3 m/s after the procedure. Over a mean follow-up of 36.6  2.7 months, ultrasound imaging indicated recurrent ISR in only 3 @entity1 at 18, 25, and 32 months after @entity16905 angioplasty, respectively. The target vessel revascularization rate was 33.3% at 36 months. No neurological or myocardial events were recorded during follow-up. One @entity1 died at 3 months. CONCLUSION: DEB may have a potential role improving outcomes of those @entity1 treated for early recurrent carotid ISR.

Long-term results of XXXX for treatment of refractory recurrent carotid in-stent restenosis.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['neointimal hyperplasia'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity16905 :: ('CHEBI:23704', 'Chemical') :: ['DEB'] @entity661 :: ('MESH:D054549', 'Disease') :: ['drug-eluting balloon (DEB) angioplasty'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']
@entity661 :: (MESH:D054549,Disease) :: ['drug-eluting balloon angioplasty']
